Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Belumosudil

Status:

Phase 2

Condition:

Lung Transplant

Intervention Type:

Oral Drug

Funder Type:

NIH | US Federal Agency

Drug Details

Belumosudil is an oral selective rho-associated coiled-coil–containing protein kinase-2 (ROCK2) inhibitor.

Study Purpose

The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s).

Find a Clinical Trial